The Claim
Omega-3 fatty acid supplementation in diabetic patients is associated with an 8.0 mg/dL reduction in apolipoprotein A-II, a component of HDL particles.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with diabetes, taking omega-3 fatty acid supplements is linked to an 8.0 mg/dL decrease in apolipoprotein A-II, a protein found in HDL cholesterol particles.
See the scientific wording
Omega-3 fatty acid supplementation in diabetic patients is associated with a significant reduction in apolipoprotein A-II by 8.0 mg/dL, a component of HDL particles, which may reflect altered HDL metabolism but whose clinical significance for cardiovascular risk remains unclear.
Omega-3 fats enter the liver and change how the body makes and repairs cholesterol-carrying particles. They reduce the production of triglyceride-rich particles, which shifts how HDL particles are built and maintained. At the same time, they trigger molecules that calm ongoing inflammation, which changes the proteins attached to HDL, including apolipoprotein A-II.
What the research says
1 studyIn people with diabetes, taking omega-3 supplements was linked to a clear drop in a protein called Apo A-II, which is part of the 'good' cholesterol. The study found this drop, just like the claim said, but it doesn't yet know if this change is good or bad for the heart.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.